| Grant number: | 18/14158-9 |
| Support Opportunities: | Scholarships abroad - Research Internship - Post-doctor |
| Start date: | November 15, 2018 |
| End date: | November 14, 2019 |
| Field of knowledge: | Health Sciences - Medicine - Medical Clinics |
| Principal Investigator: | Eliane Candiani Arantes Braga |
| Grantee: | Felipe Augusto Cerni |
| Supervisor: | Andreas Hougaard Laustsen |
| Host Institution: | Faculdade de Medicina de Ribeirão Preto (FMRP). Universidade de São Paulo (USP). Ribeirão Preto , SP, Brazil |
| Institution abroad: | Technical University of Denmark (DTU), Denmark |
| Associated to the scholarship: | 17/14035-1 - Improving of human fragment antibodies (scFvs) specific for animals' venoms, BP.PD |
Abstract The production of monoclonal antibodies (mAbs) was first described in 1975, with the discovery of the hybridoma technique. Although the hybridoma technique was described in 1975, only 10 years later, in 1985, the first monoclonal antibodies were released for therapeutic use in humans. However, only after the optimization of some techniques of these mAbs, the pharmaceutical market with monoclonal antibodies had a remarkable growth. Among the optimizations, we can highlight the recombinant DNA technology and the Phage Display technique. Recently, the representation of the monoclonal antibodies (whether murine, chimeric, humanized or human) in the pharmaceutical market is a reality, being used as the most advanced therapies for the treatment of a diversity of diseases (e.g. cancer, allergy, autoimmune diseases). With 47 mAbs already marketed in 2017, there is an expectation of more than 70 in 2020. Dr. Barbosa's group has been working with monoclonal human fragment antibodies targeting venoms for many years. Using Phage Display technology, the Barbosa's laboratory produced scFv (single-chain fragment variable) human antibodies to many venoms - Serrumab, Bothrumab, Crotumab, Lachesumab, Micrurumab and Afribumab. In this way, the group aim is to produce better antivenoms (new genetarion of antivenoms), in other words, to replace the use of heterologous antivenoms used for more than a century. However, before these antibodies reach the market, they still need to be improved regarding affinity, formats, as well as, they need some complementary tests. Therefore, the present study will improve the affinity and the formats of the Serrumab and Afribumab antibodies. | |
| News published in Agência FAPESP Newsletter about the scholarship: | |
| More itemsLess items | |
| TITULO | |
| Articles published in other media outlets ( ): | |
| More itemsLess items | |
| VEICULO: TITULO (DATA) | |
| VEICULO: TITULO (DATA) | |